keyword
MENU ▼
Read by QxMD icon Read
search

breast cancer, circulating tumor cells

keyword
https://www.readbyqxmd.com/read/29777586/platelets-autotaxin-and-lysophosphatidic-acid-signaling-win-win-factors-for-cancer-metastasis
#1
REVIEW
Raphael Leblanc, Audrey Houssin, Olivier Peyruchaud
Platelets play a crucial role in the survival of metastatic cells in the blood circulation. Interaction of tumor cells with platelets leads to the production of plethoric factors among which our review will focus on lysophosphatidic acid (LPA) because platelets are the highest producers of this bioactive lysophospholipid in the organism. LPA promotes platelet aggregation and blocking platelet function leads to inhibition of breast cancer cell metastasis through decreased LPA signaling. Autotaxin (ATX), a lysophospholipase D responsible for basal concentration of LPA in blood, was detected in platelet α-granules...
May 19, 2018: British Journal of Pharmacology
https://www.readbyqxmd.com/read/29776953/the-landscape-of-actionable-genomic-alterations-in-cell-free-circulating-tumor-dna-from-21-807-advanced-cancer-patients
#2
Oliver A Zill, Kimberly C Banks, Stephen R Fairclough, Stefanie Mortimer, James V Vowles, Reza Mokhtari, David R Gandara, Philip C Mack, Justin I Odegaard, Rebecca J Nagy, Arthur M Baca, Helmy Eltoukhy, Darya I Chudova, Richard B Lanman, AmirAli Talasaz
PURPOSE: Cell-free DNA (cfDNA) sequencing provides a non-invasive method for obtaining actionable genomic information to guide personalized cancer treatment, but the presence of multiple alterations in circulation related to treatment and tumor heterogeneity complicate the interpretation of the observed variants. Experimental Design: We describe the somatic mutation landscape of 70 cancer genes from cfDNA deep-sequencing analysis of 21,807 patients with treated, late-stage cancers across >50 cancer types...
May 18, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29775621/methylation-of-nbpf1-as-a-novel-marker-for-the-detection-of-plasma-cell-free-dna-of-breast-cancer-patients
#3
REVIEW
Dandan Li, Pengchang Li, Jie Yi, Yaling Dou, Xiuzhi Guo, Yicong Yin, Danchen Wang, Chaochao Ma, Jie Wu, Ling Qiu
BACKGROUND: Recent studies revealed that tumor-specific gene methylation can be detected in the circulating cell-free DNA (cfDNA) of cancer patients; therefore, methylated cfDNA is considered a promising biomarker. Human neuroblastoma breakpoint family member 1 (NBPF1) was originally identified in a neuroblastoma (NB) patient. The present study is the first to evaluate the presence of NBPF1 gene methylation in cell-free DNA (cfDNA) in plasma of breast cancer patients. METHODS: Differentially methylated cfDNA was screened using bisulfite sequencing with a next-generation sequencer (BS-seq) among 25 breast cancer patients, 25 patients with a benign breast disease and 25 healthy female volunteers...
May 15, 2018: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://www.readbyqxmd.com/read/29775157/blood-based-biomarkers-in-breast-cancer-from-proteins-to-circulating-tumor-cells-to-circulating-tumor-dna
#4
Michael J Duffy, Enda W McDermott, John Crown
Biomarkers are the key to personalized treatment in patients with breast cancer. While tissue biomarkers are most useful in determining prognosis and upfront predicting response to therapy, circulating protein biomarkers such as CA 15-3 and carcinoembryonic antigen are mainly used in monitoring response to endocrine or chemotherapy in patients with advanced disease. Although several centers measure biomarkers in asymptomatic patients following curative surgery for primary breast cancer, the clinical utility of this practice is unclear...
May 2018: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/29769179/rna-profiles-of-circulating-tumor-cells-and-extracellular-vesicles-for-therapy-stratification-of-metastatic-breast-cancer-patients
#5
Corinna Keup, Pawel Mach, Bahriye Aktas, Mitra Tewes, Hans-Christian Kolberg, Siegfried Hauch, Markus Sprenger-Haussels, Rainer Kimmig, Sabine Kasimir-Bauer
BACKGROUND: Liquid biopsies are discussed to provide surrogate markers for therapy stratification and monitoring. We compared messenger RNA (mRNA) profiles of circulating tumor cells (CTCs) and extracellular vesicles (EVs) in patients with metastatic breast cancer (MBC) to estimate their utility in therapy management. METHODS: Blood was collected from 35 hormone receptor-positive/HER2-negative patients with MBC at the time of disease progression and at 2 consecutive staging time points...
May 16, 2018: Clinical Chemistry
https://www.readbyqxmd.com/read/29755660/measuring-glucocorticoid-receptor-expression-in-vivo-with-pet
#6
Charles Truillet, Matthew F L Parker, Loc T Huynh, Junnian Wei, Khaled M Jami, Yung-Hua Wang, Yuqin S Shen, Renuka Sriram, David M Wilson, John Kurhanewicz, Michael J Evans
The glucocorticoid receptor (GR) is an emerging drug target for several common and deadly solid tumors like breast and prostate cancer, and clinical trials studying the antitumor effects of GR antagonists are beginning. Since GR expression can be variable in tumor cells, and virtually all normal mammalian tissues express some GR, we hypothesized that an imaging tool capable of detecting GR positive tumors and/or measuring GR occupancy by drug in tumor and normal tissues could improve the precision application of anti-GR therapies in the clinic...
April 17, 2018: Oncotarget
https://www.readbyqxmd.com/read/29746865/mir-130a-3p-inhibits-migration-and-invasion-by-regulating-rab5b-in-human-breast-cancer-stem-cell-like-cells
#7
Xiangjie Kong, Junfeng Zhang, Jia Li, Jianfeng Shao, Lin Fang
Breast cancer stem cells (BCSCs) constitute a subpopulation of tumor cells that express stem cell-associated markers and have a high capacity for tumor generation in vivo. MicroRNAs (miRNAs) are involved in tumorigenesis by regulating specific oncogenes and tumor suppressor genes, and their roles in BCSCs are becoming more apparent. We try to reveal the mechanism by which specific miRNA plays its function in BCSCs. Herein, we show that miR-130a-3p is down-regulated in human breast cancer tissues and exosomes from circulating blood...
May 10, 2018: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29744876/flubendazole-elicits-anti-metastatic-effects-in-triple-negative-breast-cancer-via-stat3-inhibition
#8
Eunhye Oh, Yoon-Jae Kim, Hyunsook An, Daeil Sung, Tae-Min Cho, Lee Farrand, Seojin Jang, Jae Hong Seo, Ji Young Kim
Tumor metastasis remains the cause of 90% of cancer-related deaths. Cancer stem cells (CSC) are thought to be responsible for the aggressive and metastatic nature of triple-negative breast cancers (TNBC), and new therapeutic strategies are being devised to target them. Flubendazole (FLU) is a widely used anthelmintic agent that also exhibits anticancer activity in several cancer types. The aim of the present study was to characterize the mechanism of action of FLU on breast cancer stem cell (BCSC)-like properties and metastasis in TNBC...
May 9, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29740925/metformin-directly-targets-the-h3k27me3-demethylase-kdm6a-utx
#9
Elisabet Cuyàs, Sara Verdura, Laura Llorach-Pares, Salvador Fernández-Arroyo, Fedra Luciano-Mateo, Noemí Cabré, Jan Stursa, Lukas Werner, Begoña Martin-Castillo, Benoit Viollet, Jiri Neuzil, Jorge Joven, Alfons Nonell-Canals, Melchor Sanchez-Martinez, Javier A Menendez
Metformin, the first drug chosen to be tested in a clinical trial aimed to target the biology of aging per se, has been clinically exploited for decades in the absence of a complete understanding of its therapeutic targets or chemical determinants. We here outline a systematic chemoinformatics approach to computationally predict biomolecular targets of metformin. Using several structure- and ligand-based software tools and reference databases containing 1,300,000 chemical compounds and more than 9,000 binding sites protein cavities, we identified 41 putative metformin targets including several epigenetic modifiers such as the member of the H3K27me3-specific demethylase subfamily, KDM6A/UTX...
May 8, 2018: Aging Cell
https://www.readbyqxmd.com/read/29739347/elevated-serum-ras-p21-is-an-independent-prognostic-factor-in-metastatic-breast-cancer
#10
Malgorzata Banys-Paluchowski, Tanja Fehm, Wolfgang Janni, Bahriye Aktas, Peter A Fasching, Sabine Kasimir-Bauer, Karin Milde-Langosch, Klaus Pantel, Brigitte Rack, Sabine Riethdorf, Erich-Franz Solomayer, Isabell Witzel, Volkmar Müller
BACKGROUND: An important component of the RAS signalling pathway, the RAS p21 oncogene, is frequently hyperactivated in breast cancer. Its expression in tumor tissue has been linked to poor clinical outcome. This study was designed to evaluate the clinical relevance of RAS p21 levels in peripheral blood in a large cohort of metastatic breast cancer patients. METHODS: Two hundred fifty-one patients with metastatic breast cancer were enrolled in this prospective, multicentre, open-label, non-randomized study...
May 8, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29737828/light-activated-ros-responsive-nanoplatform-co-delivering-apatinib-and-doxorubicin-for-enhanced-chemo-photodynamic-therapy-of-multidrug-resistant-tumors
#11
Xiao Wei, Lingqiao Liu, Xing Guo, Yi Wang, Jingya Zhao, Shaobing Zhou
Cancer chemotherapy faces the problem of the multidrug resistance (MDR) of tumor cells, which is a puzzling issue that leads to treatment failure. To address it, an innovative approach is proposed to construct a light-activated reactive oxygen species (ROS)-responsive nanoplatform based on a protoporphyrin (PpIX)-conjugated and dual chemotherapeutics-loaded polymer micelle. This system combines chemotherapy and photodynamic therapy (PDT) to defeat the MDR of tumors. Such an intelligent nanocarrier can prolong the blood circulation due to the negatively charged polysaccharide component of chondroitin sulfate (CS) and subsequently being selectively internalized by DOX-resistant human breast cancer MCF-7 cells (MCF-7/ADR)...
May 8, 2018: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/29734073/lateral-fluid-flow-fractionation-using-dielectrophoresis-lfff-dep-for-size-independent-label-free-isolation-of-circulating-tumor-cells
#12
Waqas Waheed, Anas Alazzam, Bobby Mathew, Nicolas Christoforou, Eiyad Abu-Nada
This short communication introduces a continuous-flow, dielectrophoresis-based lateral fluid flow fractionation microdevice for detection/isolation of circulating tumor cells in the presence of other haematological cells. The device utilizes two sets of planar interdigitated transducer electrodes micropatterned on top of a glass wafer using standard microfabrication techniques. A microchannel with a single inlet and two outlets, realized in polydimethylsiloxane, is bonded on the glass substrate. The two sets of electrodes slightly protrude into the microchannel...
April 30, 2018: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://www.readbyqxmd.com/read/29733541/a-multicenter-phase-ii-trial-of-neoadjuvant-letrozole-plus-low-dose-cyclophosphamide-in-postmenopausal-patients-with-estrogen-receptor-positive-breast-cancer-jbcrg-07-therapeutic-efficacy-and-clinical-implications-of-circulating-endothelial-cells
#13
Takayuki Ueno, Norikazu Masuda, Shunji Kamigaki, Takashi Morimoto, Futoshi Akiyama, Masafumi Kurosumi, Hitoshi Tsuda, Yoshiki Mikami, Sunao Tanaka, Satoshi Morita, Masakazu Toi
Neoadjuvant endocrine therapy has been reported to decrease tumor size, which leads to increased breast conservation rates. To improve the clinical response, metronomic chemotherapy with endocrine therapy is a promising strategy. A multicenter phase II single-arm neoadjuvant trial with letrozole and cyclophosphamide was conducted. Eligibility criteria included postmenopausal status, T2-4 N0-1, and estrogen receptor-positive breast carcinoma. Letrozole (2.5 mg) plus cyclophosphamide (50 mg) was given orally once a day for 24 weeks...
May 7, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29730021/obesity-and-breast-cancer-in-premenopausal-women-current-evidence-and-future-perspectives
#14
Daniela Laudisio, Giovanna Muscogiuri, Luigi Barrea, Silvia Savastano, Annamaria Colao
There is raising evidence reporting an increased incidence of breast cancer over the past decades. Every year approximately 1.4 million new cases of breast cancer are diagnosed worldwide, with a mortality rate of approximately 450,000/year. Out of these cases, 6.6% are diagnosed in premenopausal women with a median age at diagnosis of 40 years: in premenopausal women breast cancer seems to be more aggressive than in post-menopausal women. Obesity has been reported to increase the risk of developing breast cancer and to worsen the prognosis...
March 27, 2018: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/29725452/assessment-of-basal-like-breast-cancer-by-circulating-tumor-dna-analysis
#15
Wei Wei, Xianyu Zhang, Shanshan Sun, Bingshu Xia, Xiaoshuan Liang, Yan Cui, Song Gao, Da Pang
Standardized methods for the detection and assessment of circulating tumor DNA (ctDNA) in breast cancer are not sufficient. In the present study, the method and the potential application of ctDNA in the diagnosis of breast cancer were explored. DNA was extracted from the tumor tissues, plasma and peripheral blood cells of 11 patients with early-stage invasive breast cancer. Primers were designed against the exons of phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit α, p53, epidermal growth factor receptor, Akt and phosphatase and tensin homolog...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29716546/staining-of-e-selectin-ligands-on-paraffin-embedded-sections-of-tumor-tissue
#16
Mylène A Carrascal, Catarina Talina, Paula Borralho, A Gonçalo Mineiro, Ana Raquel Henriques, Cláudia Pen, Manuela Martins, Sofia Braga, Robert Sackstein, Paula A Videira
BACKGROUND: The E-selectin ligands expressed by cancer cells mediate adhesion of circulating cancer cells to endothelial cells, as well as within tissue microenvironments important for tumor progression and metastasis. The identification of E-selectin ligands within cancer tissue could yield new biomarkers for patient stratification and aid in identifying novel therapeutic targets. The determinants of selectin ligands consist of sialylated tetrasaccharides, the sialyl Lewis X and A (sLeX and sLeA ), displayed on protein or lipid scaffolds...
May 2, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29710776/circulating-tumor-cell-analysis-in-preclinical-mouse-models-of-metastasis
#17
REVIEW
Jenna Kitz, Lori E Lowes, David Goodale, Alison L Allan
The majority of cancer deaths occur because of metastasis since current therapies are largely non-curative in the metastatic setting. The use of in vivo preclinical mouse models for assessing metastasis is, therefore, critical for developing effective new cancer biomarkers and therapies. Although a number of quantitative tools have been previously developed to study in vivo metastasis, the detection and quantification of rare metastatic events has remained challenging. This review will discuss the use of circulating tumor cell (CTC) analysis as an effective means of tracking and characterizing metastatic disease progression in preclinical mouse models of breast and prostate cancer and the resulting lessons learned about CTC and metastasis biology...
April 28, 2018: Diagnostics
https://www.readbyqxmd.com/read/29701836/diagnostic-value-of-serum-concentration-and-integrity-of-circulating-cell-free-dna-in-breast-cancer-a-comparative-study-with-cea-and-ca15-3
#18
Zijie Tang, Li Li, Lei Shen, Xianjuan Shen, Shaoqing Ju, Hui Cong
Breast cancer (BC) is one of the most common types of malignant neoplasm in women; the incidence of BC increases yearly. In a previous study, a novel and sensitive method for quantitying cell-free DNA (CFD) in human blood was established and tested for its ability to predict which patients harbored tumors. Our objective in this study was to investigate the clinical value of serum concentration and the integrity of circulating free DNA (CFD) as a biomarker for auxiliary diagnosis of BC. The concentration of CFD was quantitated by branched DNA (bDNA)-based Alu assay...
April 26, 2018: Laboratory Medicine
https://www.readbyqxmd.com/read/29697206/subtyping-of-magnetically-isolated-breast-cancer-cells-using-magnetic-force-microscopy
#19
Kyeong-Jun Kim, Hyeon-Yeol Cho, Won-Jun Lee, Jeong-Woo Choi
Circulating tumor cell (CTC) which recently arisen as potential sources for monitoring and characterizing non-haematologic cancers and their metastatic derivatives. Immunomagnetic microbeads and magnetic nanoparticles (MNPs) have been extensively explored to isolate CTCs from blood samples. However, MNPs attached on the membrane protein are interrupted further analysis to distinguish the cancer subtype by consumption or blocking the target surface marker. Here, we describe an MNP-mediated analysis method for surface marker expression profile by magnetic force microscopy (MFM)...
April 26, 2018: Biotechnology Journal
https://www.readbyqxmd.com/read/29689598/correlation-between-circulating-cell-free-pik3ca-tumor-dna-levels-and-treatment-response-in-patients-with-pik3ca-mutated-metastatic-breast-cancer
#20
Annette R Kodahl, Sidse Ehmsen, Niels Pallisgaard, Anne Marie B Jylling, Jeanette Dupont Jensen, Anne-Vibeke Laenkholm, Ann S Knoop, Henrik J Ditzel
Liquid biopsies focusing on the analysis of circulating cell-free tumor DNA (ctDNA) may have important clinical implications for personalized medicine, including early detection of cancer, therapeutic guidance and monitoring of recurrence. Mutations in the oncogene, PIK3CA, are frequently observed in breast cancer and have been suggested as a predictive biomarker for PI3K-selective inhibitor treatment. In this study, we analyzed the presence of PIK3CA mutations in formalin-fixed, paraffin-embedded, metastatic tissue and corresponding ctDNA from serum of patients with advanced breast cancer using a highly-sensitive, optimized droplet digital PCR (ddPCR) assay...
April 24, 2018: Molecular Oncology
keyword
keyword
99352
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"